Miloš K.
- Country
- Czechia
- Department
- Klinika kardiologie
Research Overview
- A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
- Evaluation of Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: A Randomized, Double-blind, Placebo-controlled Study
- Efficacy and Safety Evaluation of ALXN2220 in Adult Patients with Transthyretin Amyloid Cardiomyopathy: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Data & Insights
Has run more than one trial at 118 of 213 partner sites.
Specializations
Cardiomyopathy Research
The investigator specializes in various forms of cardiomyopathy, with particular emphasis on transthyretin amyloid cardiomyopathy (ATTR-CM) and hypertrophic cardiomyopathy (HCM).
- Non-obstructive Hypertrophic Cardiomyopathy
- Obstructive HCM
- ATTR Amyloidosis with Cardiomyopathy
Their research encompasses cardiac structure evaluation and functional capacity assessment in cardiomyopathy patients.
Therapeutic Innovations
The investigator explores novel therapeutic approaches for cardiac conditions, including emerging treatments such as mavacamten, eplontersen, and acoramidis.
- Transthyretin Stabilizers
- RNA-targeted Therapeutics
- Long-term Safety Studies
Their work focuses on evaluating treatment efficacy and safety in cardiovascular disease management.
Clinical Outcomes
The investigator studies key clinical outcomes in cardiovascular disease, with particular attention to patient health status and exercise capacity.
- Cardiovascular Clinical Events
- Exercise Capacity Assessment
- Patient-Reported Outcomes
Their research evaluates treatment effects on physical limitations and cardiovascular mortality.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.